12月8日 - ** Ocular Therapeutix OCUL.O 的股票在盘前交易中上涨 13.5% 至 14.28 美元
** OCUL 表示，公司计划在目前正在进行的晚期试验取得一年的数据后，为其治疗湿性年龄相关性黄斑变性的实验性眼病药物 Axpaxli 提交上市申请，预计时间为 2026 年第一季度。
** 湿性老年黄斑变性是老年人视力丧失的主要原因，其特征是视网膜血管异常增生
** 公司表示，该研究旨在显示其优于Regeneron Pharma公司REGN.O的Eylea，并符合FDA最近的指导意见，即一项单一的、对照良好的试验可支持审批
** 截至上一交易日收盘，股价累计上涨 47.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.